By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Atossa Genetics, Inc. 

4105 East Madison Street
Suite 320
Seattle  Washington  98112  U.S.A.
Phone: 206-325-6086 Fax: 206-325-6087


Company News
Atossa Genetics (ATOS) Completes Enrollment In Topical Arm Of Endoxifen Phase I Study 5/25/2017 6:21:23 AM
Atossa Genetics (ATOS) Announces First Quarter 2017 Financial Results And Provides Company Update 5/16/2017 5:57:29 AM
Atossa Genetics (ATOS) Receives Approval From Institutional Review Board For Continuation Of Its Fulvestrant Microcatheter Phase 2 Study 5/10/2017 1:08:34 PM
Atossa Genetics (ATOS) Receives Positive Interim Review From Independent Safety Committee In Phase I Endoxifen Dose Escalation Study 4/21/2017 12:59:38 PM
Atossa Genetics (ATOS) Enrolls First Cohort Of Eight Subjects In Endoxifen Study 4/4/2017 10:49:55 AM
Atossa Genetics (ATOS) Closes Public Offering 4/3/2017 2:34:39 PM
Atossa Genetics (ATOS) Prices $4,000,000 Public Offering 3/30/2017 1:23:15 PM
Atossa Genetics (ATOS) Opens Enrollment In Study Of Endoxifen 3/24/2017 9:26:01 AM
Atossa Genetics (ATOS) Provides Update On Its Phase 2 Study Of Fulvestrant Administered With Its Microcatheter 1/9/2017 11:25:30 AM
Atossa Genetics (ATOS) Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) As Scientific Advisor 12/27/2016 11:56:07 AM